Multiple recent independent studies identified LTBP2 as a serum biomarker for pulmonary fibrosis associated with poor clinical outcomes, including a large unbiased screen in which LTBP2 was the strongest negative predictor of transplant-free survival of all measured proteins, with a hazard ratio of 2.4311-13. The gene discussed is LTBP2; the disease is pulmonary fibrosis.